Hiteck(SZ:300683)2025-04-25 08:02Group 1: Company Performance - The company achieved a revenue of 157 million yuan in Q1 2025, representing an 18.79% year-on-year increase [3] - The net profit attributable to the parent company was approximately -13.93 million yuan, an increase of 15.81% year-on-year [3] - The operating cash flow net amount dropped significantly by 644.52% year-on-year [2] Group 2: R&D and Product Development - The company is focused on improving R&D efficiency by establishing a comprehensive project management system and optimizing the R&D structure [2] - The new drug Epinavim is expected to be officially launched in May 2024 and will enter the national medical insurance directory, becoming a new profit growth point [2] - The company is actively promoting Epinavim's market entry and has received export sales certification [3] Group 3: Financial Strategy and Shareholder Relations - The company distributed approximately 17 million yuan in mid-year dividends for 2024, despite a net loss of about 69 million yuan for the year [6] - The management is committed to maximizing shareholder interests and improving operational performance [6] - The company plans to enhance competitiveness through product differentiation and cost control strategies [4] Group 4: Industry Outlook - The biopharmaceutical industry is experiencing continuous growth, with no signs of overcapacity or technological decline [2] - The company aims to maintain its market share and improve sales through direct sales and partnerships with professional promoters [5]